



# CHBG NEWSLETTER

## The Cochrane Hepato-Biliary Group (CHBG)

Volume 11, Issue 1

March 2007

### IN THIS ISSUE

**NEW PUBLICATIONS IN THE CLIB ISSUE 1 AND 2, 2007**

**NEW REGISTERED TITLES**

**REVIEWS AND PROTOCOLS EXPECTED TO BE PUBLISHED IN THE CLIB ISSUE 3 OR 4, 2007**

**REVIEWS IN NEED TO BE UPDATED**

#### PAST EVENTS

- MEETING ON INTERNATIONAL GUIDELINES ON CHELATING AGENTS, NAPLES, ITALY
- EUROPEAN CLINICAL RESEARCH INFRASTRUCTURES NETWORK (ECRIN) MEETING, LONDON, UK
- 14<sup>TH</sup> COCHRANE COLLOQUIUM, DUBLIN; IRELAND
- 55<sup>TH</sup> ANNUAL AASLD MEETING, BOSTON, MA, USA

#### FUTURE EVENTS

- THE 42nd ANNUAL EASL 2007 MEETING
- TRAIN THE TRAINERS
- 4th NATIONAL COURSE ON DIGESTIVE ENDOSCOPY
- ECRIN KICK-OFF MEETING
- ECRIN WORKING PARTY WORKSHOP
- INTERNATIONAL CLINICAL TRIALS' DAY
- DIGESTIVE DISEASE WEEK (DDW) 2007
- CONTINENTAL EUROPEAN COCHRANE ENTITIES MEETING

#### WILEY PUBLICITY CAMPAIGN

#### VISITS

#### PEER REVIEWERS

#### COLLABORATION NEWS

#### MISCELLANEOUS

#### NOTE

*The numbering is a continuation from Vol.10, Issue 2, 2006*

### NEW PUBLICATIONS IN THE CLIB ISSUE 1 AND 2, 2007

#### NEW REVIEWS

63. Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease. Marti-Carvajal AJ, Pérez-Requejo JL.
64. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F.
65. Bicyclol for chronic hepatitis C. Yang XY, Zhuo Q, Wu TX, Liu GJ.
66. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Orlando R, Azzalini L, Orando S, Lirussi F.
67. Cholecystectomy versus no cholecystectomy in patients with silent gallstones. Gurusamy KS, Samraj K.
68. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F.
69. Elective surgery for benign liver tumours. Colli A, Fraquelli M, Massironi S, Colucci A, Paggi S, Conte D.
70. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases. Marti-Carvajal AJ, Salanti G, Marti-Carvajal PI.
71. Primary closure versus T-tube drainage after laparoscopic common bile duct stone exploration. Gurusamy KS, Samraj K.



72. Primary closure versus T-tube drainage after open common bile duct exploration. Gurusamy KS, Samraj K.
73. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Lirussi F, Mastropasqua E, Orando S, Orlando R.
74. Routine abdominal drainage for uncomplicated open cholecystectomy. Gurusamy KS, Samraj K.

#### UPDATED REVIEWS

None.

#### NEW PROTOCOLS

129. Antibiotics for hepatic encephalopathy. Falavigna M, Kieling C, Wolff FH, Medeiros LR, Cheinquer H.
130. Ischaemic preconditioning versus no ischaemic preconditioning for liver transplantation. Gurusamy KS, Kumar Y, Davidson BR.
131. Methods of vascular occlusion for liver resections. Gurusamy KS, Kumar Y, Davidson BR.
132. Non-steroid anti-inflammatory drugs for biliary colics. Colli A, Conte D, Sciola V, Fraquelli M.
133. Pegylated interferon for acute hepatitis C. Simin M, Myers RP, Stimac D, Gluud C.
134. Pegylated interferon for chronic hepatitis B. Mumtaz K, Hamid S, Brok J, Jafri W.
135. Beta-blockers alone or with endoscopic therapy for prevention of variceal rebleeding in portal hypertension. Sharma BC, Gluud LL, Sarin SK.
136. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. Mathew JL, El Dib R, Mathew PJM, Boxall EH, Brok J.
137. Lamivudine for chronic hepatitis B in adults. Mumtaz K, Subhan A, Hamid S, Jafri W.

#### UPDATED PROTOCOLS

None.

#### NEW REGISTERED TITLES

249. Abdominal lift for laparoscopic cholecystectomy.

- Gurusamy KS et al.
250. Absorbable versus non-absorbable occlusion of cystic duct for laparoscopic cholecystectomy. Gurusamy KS et al.
251. Antioxidant supplements for primary and secondary prevention of mortality. Bjelakovic G et al.
252. Antiviral therapy for patients with hepatitis C virus undergoing liver transplantation. Gurusamy KS et al.
253. Antiviral prophylactic intervention for hepatitis C virus in patients undergoing liver transplantation. Gurusamy KS et al.
254. Bariatric surgery for non-alcoholic steatohepatitis. Chavez-Tapia NC et al.
255. Cholecystectomy versus no cholecystectomy after endoscopic sphincterotomy for patients with common bile duct stones. Gurusamy KS et al.
256. Cholecystectomy versus no cholecystectomy for gallbladder dyskinesia. Gurusamy KS et al.
257. Cholecystectomy versus no cholecystectomy for gallbladder polyp. Gurusamy KS et al.
258. Cholecystectomy versus no cholecystectomy for high-risk surgical patients with symptomatic gallstones. Gurusamy KS et al.
259. Day-case Bariatric surgery for non-alcoholic steatohepatitis. Chavez-Tapia NC, et al.
260. Day-case versus overnight stay for laparoscopic cholecystectomy. Gurusamy KS et al.
261. Early versus delayed laparoscopic cholecystectomy for biliary colic. Gurusamy KS et al.
262. Four ports versus fewer than four ports for laparoscopic cholecystectomy. Gurusamy KS et al.
263. Immunoprophylaxis for patients with hepatitis C virus undergoing liver transplantation. Gurusamy KS et al.
264. Interventions for adult polycystic liver disease. Stoot J et al.
265. Intra-peritoneal local anaesthetic instillation versus no instillation for laparoscopic cholecystectomy. Gurusamy KS et al.
266. Intra-peritoneal saline instillation versus no instillation for laparoscopic



- cholecystectomy. Gurusamy KS et al.
267. Liver resection versus non-surgical treatment for hepatic node positive patients with colorectal metastases. Gurusamy KS et al.
  268. Liver resection versus other treatments for neuroendocrine tumours in patients with potentially resectable liver metastases. Gurusamy KS et al.
  269. Methods of decreasing wound infection for liver resection. Gurusamy KS et al.
  270. Methods of gallbladder dissection for laparoscopic cholecystectomy. Gurusamy KS et al.
  271. Methods of preventing bacterial sepsis and wound complications for liver transplantation. Gurusamy KS et al.
  272. Methods to decrease blood loss for liver transplantation. Gurusamy KS et al.
  273. Miniport versus standard ports for laparoscopic cholecystectomy. Gurusamy KS et al.
  274. Non-invasive tests for the diagnosis of esophageal varices in patients with cirrhosis. Gana JC et al.
  275. Non-surgical interventions to decrease blood loss for liver resection. Gurusamy KS et al.
  276. Non-surgical methods to reduce ischaemia-reperfusion injury for liver resections performed under vascular control. Gurusamy KS et al.
  277. Palliative liver resection versus other treatments for neuroendocrine tumours when curative liver resection is not possible. Gurusamy KS et al.
  278. Pharmacological interventions to reduce reperfusion injury for liver transplantation. Gurusamy KS et al.
  279. Plastic stents versus metal stents versus metal stents for endoscopic management of biliary strictures. Gurusamy KS et al.
  280. Robot assistant for laparoscopic cholecystectomy. Gurusamy KS et al.
  281. Routine drainage for orthotopic liver transplantation. Gurusamy KS et al.
  282. Standard versus piggy-back graft for liver transplantation. Gurusamy KS et al.
  283. Techniques of biliary reconstruction for liver transplantation. Gurusamy KS et al.
  284. Techniques of liver parenchymal transaction for liver resection. Gurusamy KS et al.
  285. Techniques of reperfusion for liver transplantation. Gurusamy KS et al.
  286. Topical haemostatic agents for liver resection. Gurusamy KS et al.
  287. Two-dimensional versus three dimensional imaging for laparoscopic cholecystectomy. Gurusamy KS et al.
  288. Veno-venous bypass versus none for liver transplantation. Gurusamy KS et al.
  289. Virtual reality training for surgical trainees in laparoscopic surgery. Gurusamy KS et al. stay for laparoscopic cholecystectomy. Gurusamy KS et al.
  290. Wound infiltration with local anaesthetic agents versus no instillation for laparoscopic cholecystectomy. Gurusamy KS et al.

**REVIEWS AND PROTOCOLS EXPECTED TO BE PUBLISHED IN THE CLIB ISSUE 3 OR 4, 2007**

**REVIEWS**

1. Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomy  
Sanabria A, Valdivieso E, Gomez G, Dominguez LC.
2. Antioxidant supplements for primary and secondary prevention of mortality. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C.
3. Azathioprine for primary biliary cirrhosis. Gong Y, Christensen E, Gluud C.
4. Banding ligation versus beta-blockers for primary prevention of bleeding oesophageal varices. Gluud LL, Klingenberg SL, Nikolova D, Gluud C.
5. Beta-blockers alone or with endoscopic therapy for prevention of variceal rebleeding in portal hypertension. Sharma BC, Gluud LL, Sarin SK.
6. Cyclosporin A for primary biliary cirrhosis. Gong Y, Christensen E, Gluud C.
7. Endoscopic retrograde cholangio-pancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgery. Mumtaz K, Hamid S, Jafri W.
8. Glucocorticosteroids for alcoholic hepatitis. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C.



9. Immunoglobulins for preventing hepatitis A. Liu JP, Yang M, Du XM.
10. Ischaemic preconditioning versus no ischaemic preconditioning for liver transplantation. Gurusamy KS, Kumar Y, Sharma D, Davidson BR.
11. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C. Simin M, Brok J, Stimac D, Gluud C, Gluud LL.
12. Peg interferon alpha 2a versus pegylated interferon alpha 2b for acute and chronic hepatitis C. Simin M, Stimac D, Gluud C.
13. Pegylated interferon for acute hepatitis C. Simin M, Myers RP, Stimac D, Gluud C.
14. Preoperative biliary drainage for obstructive jaundice. Wang C, Gurusamy KS, Wang Q, He L, Xie X.
15. Routine abdominal drainage for uncomplicated laparoscopic cholecystectomy. Gurusamy KS, Samraj K, Mullerat P, Davidson BR.
16. Routine abdominal drainage for uncomplicated liver resection. Gurusamy KS, Samraj K, Davidson BR.
7. Day-case versus overnight stay for laparoscopic cholecystectomy. Gurusamy KS, Junnarkar S, Davidson BR.
8. Effect of different pressures of pneumoperitoneum in laparoscopic cholecystectomy. Gurusamy KS, Samraj K, Davidson BR.
9. Entecavir for chronic hepatitis B. Woo G, Pritchett S, Krahn M.
10. Gallbladder in-situ after endoscopic sphincterotomy versus cholecystectomy during or after treatment of common bile duct stones for patients with common bile duct stones. Gurusamy KS, Imber C, Farouk M, Davidson BR.
11. Imidazole derivatives for uncomplicated amoebic liver abscess. Mumtaz K, Hamid S, Jafri W.
12. Methods of management of high-risk surgical patients with acute cholecystitis. Gurusamy KS, Kumar Y, Farouk M, Davidson BR.
13. Methods of preventing bacterial sepsis and wound complications for liver transplantation. Gurusamy KS, Kumar Y, Davidson BR.
14. Miniport versus standard ports in laparoscopic cholecystectomy. Gurusamy KS, Samraj K, Davidson BR.
15. Non-invasive tests for the diagnosis of esophageal varices. Gana JC, Turner D, Zachos M, Ling SC.
16. Plastic stents versus metal stents for endoscopic management of malignant biliary tract strictures. Kassem AM, Ibrahim M.
17. Robot assistant for laparoscopic cholecystectomy. Gurusamy KS, Samraj K, Davidson BR.
18. Techniques for liver parenchymal transection in liver resection. Gurusamy KS, Pamecha V, Sharma D, Davidson BR.
19. Virtual reality training for surgical trainees in laparoscopic surgery. Gurusamy KS, Aggarwal R, Palanivelu L, Davidson BR.

#### PROTOCOLS

1. Abdominal lift for laparoscopic cholecystectomy. Gurusamy KS, Samraj K, Davidson BR.
2. Antiviral prophylactic intervention for hepatitis C virus in patients undergoing liver transplantation. Gurusamy KS, Samraj K, Davidson BR.
3. Antiviral therapy in patients with hepatitis C virus undergoing liver transplantation. Gurusamy KS, Samraj K, Davidson BR.
4. Cholecystectomy versus no cholecystectomy for gallbladder polyp. Gurusamy KS, Kumar Y, Farouk M, Davidson BR.
5. Cholecystectomy versus no cholecystectomy for suspected gallbladder dyskinesia. Gurusamy KS, Junnarkar S, Farouk M, Davidson BR.
6. Combination of beta-blocker plus nitrate for prevention of variceal rebleeding in portal hypertension. Sharma BC, Gluud LL, Sarin SK.
1. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Chan ES-Y, Chow PK-H, Machin D, Soo K-C, Samuel M.

#### UPDATED REVIEWS FOR ISSUE 3 OR 4 OF THE COCHRANE LIBRARY



2. Ursodeoxycholic acid for primary biliary cirrhosis. Gong Y, Huang ZB, Christensen E, Gluud C.

Presently three reviews are sent to the CHBG Editors for final comments before acceptance for publication in Issue 3 2007; another nine reviews are expected to be sent by October 2007.

#### REVIEWS IN NEED TO BE UPDATED

As we wrote in Issue 2 2006 of The CHBG Newsletter, the number of outdated CHBG reviews is increasing. Since January 2007, Sarah Louise Klingenberg, The CHBG Trials Search Co-ordinator, is contacting authors of outdated reviews inquiring when the review will be updated. We have received replies from some of the authors and we thank for this. If, however, any of the authors, for some reason, cannot maintain a published review, then we would appreciate a lot if we get a notification soonest possible. In such case, we will feel free to offer the review to other interested people.

Sarah Louise Klingenberg will be on maternity leave from July this year and will not return before the summer of 2008. During her leave, searches for reviews will not be performed to authors.

Please note that any change to a Cochrane review is either an update or an amendment. An update always involves a search for new studies with incorporation of any newly identified studies in the review. Any other change to a Cochrane review constitutes an amendment. Reviews that undergo important changes (whether updates or amendments) warrant new citations in the Cochrane Database of Systematic Reviews and new MEDLINE/ISI record (examples might include changes to conclusions or correcting serious errors). These will now be referred to as 'new citation versions'. (The date in bracket refers to the last search result sent to authors with a request to update the review).

You may find more detail at

<http://cochrane.org/docs/DatesandUpdatesinCochraneReviews.doc>

1. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Wun YT, Dickinson JA. (January 2007)
2. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L. (January 2007)
3. Antibiotics for leptospirosis. Guidugli F, Castro AA, Atallah AN. (January 2007)
4. Antibiotics for preventing leptospirosis. Guidugli F, Castro AA, Atallah AN. (January 2007)
5. Antibiotics for spontaneous bacterial peritonitis in cirrhotics. Soares-Weiser K, Brezis M, Leibovici L. (January 2007)
6. Artificial and bioartificial support systems for liver failure. Liu JP, Gluud LL, Als-Nielsen B, Gluud C. (November 2006)
7. Benzodiazepine receptor antagonists for hepatic encephalopathy. Als-Nielsen B, Gluud LL, Gluud C. (Searches not updated yet.)
8. Bile acids for primary sclerosing cholangitis. Chen W, Gluud C. (January 2007)
9. Bile acids for viral hepatitis. Chen W, Liu J, Gluud C. (January 2007)
10. Branched-chain amino acids for hepatic encephalopathy. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. (September 2006)
11. Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection. Liu JP, McIntosh H, Lin H. (December 2005)
12. Chinese medicinal herbs for chronic hepatitis B. Liu JP, McIntosh H, Lin H. (October 2005)
13. Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. (January 2007)
14. Interferon for acute hepatitis C. Myers RP, Regimbeau C, Thevenot T, Leroy V,





Mathurin P, Opolon P, Zarski JP, Poynard T.  
(January 2007)

15. Medicinal herbs for hepatitis C virus infection. Liu JP, Manheimer E, Tsutani K, Gluud C. (June 2006)
16. Nonabsorbable disaccharides for hepatic encephalopathy. Als-Nielsen B, Gluud LL, Gluud C. (Searches not updated yet)
17. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Galandi D, Antes G. (January 2007)
18. Sphincterotomy for biliary sphincter of Oddi dysfunction. Craig AG, Toouli J. (January 2007)
19. Terlipressin for acute esophageal variceal hemorrhage. Ioannou G, Doust J, Rockey DC. (January 2007)
20. Ursodeoxycholic acid and/or antibiotics for prevention of biliary stent occlusion. Galandi D, Schwarzer G, Bassler D, Allgaier HP. (January 2007)

## PAST EVENTS

MEETING ON INTERNATIONAL GUIDELINES ON CHELATING AGENTS  
October 6 to 9, 2006, Naples, Italy.

Christian Gluud chaired the meeting, organised by Aurelio Maggio, Italy. The aim of the meeting was to review the efficacy and calculate the cost of main interventions for prevention and treatment of secondary haemochromatosis in patients with haemoglobinopathies.

EUROPEAN CLINICAL RESEARCH INFRASTRUCTURES NETWORK (ECRIN) MEETING  
October 12, 2006, London, UK.

The ECRIN kick-off meeting took place in the Medical Research Council's Clinical Trial Unit. The agenda items included roles of the co-ordination and national networks and their participation in workshops. Christian Gluud attended the meeting, representing DCRIN.

For information on what ECRIN is, their objectives, etc. please visit <http://www.ecrin.org/>.

14TH COCHRANE COLLOQUIUM  
October 23 to 26, 2006, Dublin, Ireland.

Present were 800 members from over 40 different countries. Jianping Liu, Ronald Koretz, Dimitrinka Nikolova, Sarah Klingenberg, Kristian Thorlund, and Christian Gluud participated.

55TH ANNUAL AASLD MEETING  
October 30, 2006, Boston, MA, USA.

The 21st Cochrane CHBG bi-annual meeting, during the 55th annual AASLD meeting, Boston, (October 27 to October 31, 2006) was on October 30. We wish to thank those who attended it.

## FUTURE EVENTS

THE 42nd ANNUAL EASL 2007 MEETING  
April 11 to 15, Barcelona, Spain.

The CHBG will man a stand during the EASL exhibition. Should you wish to talk with us, you will find us at stand no 42. We kindly thank EASL for sponsoring the stand. The CHBG will not run a meeting this year.

TRAIN THE TRAINERS  
April 14 to 21 April, 2007, Porto, Portugal.

Jim Toouli and an international faculty will run a five-day course on evidence-based medicine. Christian Gluud is on the Faculty. There will be 50 participants from around the world.

4th NATIONAL COURSE ON DIGESTIVE ENDOSCOPY  
April 21 to 26 Porto, Portugal.

Christian Gluud is among the invited speakers.

ECRIN KICK-OFF MEETING  
May 10, Copenhagen, Denmark.  
Meeting focusing on the necessity of networks and transparency within clinical research. For more information please go to [http://www.biologue.ku.dk/English\\_Version/Events/20070510\\_ECRIN/Workshop10May2007.htm](http://www.biologue.ku.dk/English_Version/Events/20070510_ECRIN/Workshop10May2007.htm)

ECRIN WORKING PARTY WORKSHOP  
May 19 to 21, Paris, France.



All 8 Working Parties will meet in Paris in order to make status on the work and project the future work to be done within ECRIN.

**INTERNATIONAL CLINICAL TRIALS' DAY**  
May 20, 2007, Paris France.

The third International Clinical Trials' Day will be celebrated in Paris in connection to the ECRIN meeting there. Main speaker will be Silvio Garattini from the world famous Mario Negri Institute, a representative from EURORDIS, and Jacques Demotes-Mainard, ECRIN. For further information, please contact Christian Gluud, who will chair the meeting.

**DIGESTIVE DISEASE WEEK (DDW) 2007**  
May 19 to 24, Washington Convention Center, Washington DC, USA.

The Inflammatory Bowel Disease and Functional Bowel Disorders Group will run a symposium entitled 'Controversies and consensus: how Cochrane reviews guide therapy in inflammatory bowel disease' on May 21, 2007 from 4:00 a.m. to 5:30 a.m. at the Washington Convention Center .

The Inflammatory Bowel Disease and Functional Bowel Disorders Group will also man a stand at which they will also represent The CHBG during the DDW exhibition. You are kindly invited to pay them a visit. Any questions that you might have, they will forward to us. At the stand, you may apply for a monthly free access to the CLib.

**CONTINENTAL EUROPEAN COCHRANE ENTITIES MEETING**  
June 13 to 14, Oslo, Norway

A meeting for European review group staff is organised, sponsored, and hosted by The Nordic Cochrane Centre.

#### **WILEY PUBLICITY CAMPAIGN**

Wiley are involved with the Center for Advancement of Health (CFAH) in Washington DC, who in turn work with Health Behavior

News Service (HBNS) to distribute news releases on reviews to be published in The CLib.

Authors of Cochrane reviews may be approached by HBNS reporters who are in charge of drafting and disseminating press releases based on forthcoming reviews.

A HBNS reporter, with an assigned review to cover, should present himself in the following way:

I am XXXX, a reporter with Health Behavior News Service (HBNS). I have been assigned to write a news story on the upcoming Cochrane Library Review on XXXX. HBNS has a working relationship with the Center for Advancement in Health and with Wiley, the global publisher of The Cochrane Library to disseminate findings from Cochrane reviews to the media, especially in the United States.

The story will not appear on the public HBNS news site until the embargo is lifted on XX 2007, to coincide with publication of Issue X, 2007 of the Cochrane Library. The HBNS story will be available only to journalists on our password-protected list, a week or so prior to the embargo, to give reporters time to conduct interviews.

Wiley also does stand-alone press releases. These press materials are written by a freelancer, Dr Pete Moore, and he'll be approaching the review authors for their comments.

#### **VISITS**

*Andrea Rambaldi*, Italy, visited the Editorial Team Office for a week in January 2007. Andrea worked on the review 'Glucocorticosteroids for alcoholic hepatitis'.

*Eric Keus*, The Netherlands, visited the Editorial Team Office for a week from February 27 to March 2, 2007. Eric worked on an Overview of Cochrane Reviews.

An overview of reviews is a summary of results



of published Cochrane reviews on one and the same clinical question, the range of interventions covered, and the outcomes considered. The format of RevMan 5 will allow the publication of this kind of reviews. Presently, overview reviews are to be found in the Evidence-based child health: a Cochrane review journal.

*Kees van Laarhoven, The Netherlands*, visited the Editorial Team Office for a day March 2. Together with Eric Keus, he works on reviews.

### PEER REVIEWERS

From Issue 3 of The CLib, peer reviewers of CHBG reviews and protocols will find their names listed for each year. In this way, their contribution will be more evident.

### COLLABORATION NEWS

#### REVMAN SOFTWARE

RevMan, the Cochrane Collaboration's statistical software, is mandatory for production and input of data into Cochrane systematic reviews. A major update of the RevMan writing software is due to be released during the latter half of 2007.

*RevMan 5* will result in additional changes to The Cochrane Database of Systematic Reviews (CDSR). Cochrane Methodology Reviews will be integrated with Intervention Reviews, rather than appearing separately as they do now. CDSR will also include Diagnostic Test Reviews and Overviews of Reviews (previously named 'umbrella reviews'). Among other new features, RevMan 5 will contain two new types of tables (Risk of Bias Tables and Summary of Findings Tables).

#### ESTABLISHMENT OF THE COCHRANE DEVELOPING COUNTRIES NETWORK (CDCN)

The CDCN is a new Cochrane entity, with a focus on involving collaborators from developing countries in the work of The Cochrane Collaboration is established. If you wish to get in touch, use the address below.  
<http://dcn.cochrane.org/>.

#### COCHRANE LIBRARY NOW FREELY AVAILABLE IN INDIA

The Cochrane Library is now freely available to all residents of India with Internet access thanks to funding from the Indian Council of Medical Research (ICMR). More information from The Indian newspaper, The Telegraph, [http://www.telegraphindia.com/1070204/asp/nation/story\\_7348274.asp](http://www.telegraphindia.com/1070204/asp/nation/story_7348274.asp).  
or at  
[http://www.cochrane.org/press/wiley/2007.08.02.Indian\\_Provision\\_Press\\_Release.pdf](http://www.cochrane.org/press/wiley/2007.08.02.Indian_Provision_Press_Release.pdf).

For a full list of free availability of The CLib, look under "Access to Cochrane" on the Cochrane Library's homepage via John Wiley & Sons.

#### COCHRANE LIBRARY NOT FREELY AVAILABLE IN DENMARK ANY MORE

The Cochrane Library is now no longer freely available to all residents in Denmark. With the establishment of a regional health-care system condensed into five regions someone has managed to turn the free national access to The CLib for all Danish citizens into one restricted to Danish health-care workers and certain health-care students. People knowing the economics behind the change state that not a single Danish krone seems to have been saved! The people behind this move and their intentions are not yet fully known. Some say that the paternalistic move may be directed to cover up the gap between evidence and practice in Denmark.

### MISCELLANEOUS

#### HOW TO REPORT IN THE RESULTS SECTION

The results section should include the following according to the Handbook: "The results section should be a summary of the main findings on the effects of the interventions studied in the review. The section should directly address the objectives of the review rather than list the findings of the included studies in turn. The results of individual studies, and any statistical summary of these, should be included in Data tables and forest plots. Subheadings are encouraged in the Results





section if they make reading easier (for example, for each different participant group, comparison or outcome measure if a review addresses more than one). Any sensitivity analyses that were undertaken should be reported.

In addition Johnny Boesen, CHBG consumer representative, requests that absolute risk proportions be given for the individual outcome measure. That is, the structure of reporting of a dichotomous outcome measure could be:

Combining the results of the five randomised clinical trials demonstrated no significant effect of anabolic-androgenic steroids versus placebo or no intervention on mortality (RR 1.01, 95% confidence interval (CI) 0.79 to 1.29). In the anabolic-androgenic steroids group 87/275 (31.6%) patients died versus 73/224 (32.6%) patients in the control group (Comparison 01-01).

THE COCHRANE COLLABORATION WEB SITE  
Due to the limited space, we cannot inform in details about new reports or policies of The

Cochrane Collaboration or the working activities within entities. That is why we can only recommend that you visit regularly The Cochrane Collaboration web site to follow the news connected with policy decisions, updates of materials for authors, and software programmes. See <http://www.cochrane.org>

Information about **workshops** run in different countries you will find at <http://www.cochrane.org/news/workshops.shtml>

Information about **fellowships, scholarships, and bursaries**, you will find at <http://www.cochrane.org/docs/Fellowshipsandscholarships.htm>

#### NOTE

The CHBG Newsletter has International Standard Serial Number (ISSN). This is a unique eight-digit number assigned to every serial publication. Information about the publication will be added to international databases. You will see it on the top right corner of the first page.

The bi-yearly Cochrane Hepato-Biliary Group (CHBG) Newsletter is written, edited, and published in electronic and paper format by staff at The CHBG Editorial Base in Copenhagen, Denmark. It is issued twice a year and distributed for free world-wide to all people on The CHBG members list who either have contributed, are contributing, or show interest in the work of The CHBG. The purpose is to inform the readers about activities within The CHBG.

Editorial CHBG staff at The CHBG Editorial Base: Christian Gluud, Co-ordinating & Criticism Editor, E-mail: [cgluud@ctu.rh.dk](mailto:cgluud@ctu.rh.dk); Dimitrinka Nikolova, Review Group Co-ordinator, E-mail: [dnikolov@ctu.rh.dk](mailto:dnikolov@ctu.rh.dk); Sarah Louise Klingenberg, Trials Search Co-ordinator, E-mail: [slk@ctu.rh.dk](mailto:slk@ctu.rh.dk); Nader Salas, IT Advisor and Web Master, E-mail: [nader.s@ctu.rh.dk](mailto:nader.s@ctu.rh.dk); Styrbjørn Birch, IT help E-mail: [s.birch@ctu.rh.dk](mailto:s.birch@ctu.rh.dk)

*Postal address:* Cochrane Hepato-Biliary Group, Copenhagen Trial Unit,  
Centre for Clinical Intervention Research  
Dept.33.44., H:S Rigshospitalet, Blegdamsvej 9, DK-2100  
Copenhagen Ø, Denmark,  
Tel. +45 3545 7169 or +3545 7175, Fax +45 3545 7101,  
E-mail: [dnikolov@ctu.rh.dk](mailto:dnikolov@ctu.rh.dk)  
Web site: <http://ctu.rh.dk/chbg>

*Visiting address:* Nørre Alle 20, DK-2200, Copenhagen N

